- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02436421
Impact of Best Practice Alerts in Cardiology Outpatient Clinics
November 29, 2016 updated by: Duke University
This quality improvement intervention seeks to implement two Best Practice Alerts (BPAs) for use in cardiology clinics while simultaneously evaluating the impact of each BPA- one for patients with uncontrolled blood pressure and one for patients with atrial fibrillation not on anticoagulation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Best Practice Alerts based will be created for hypertension and atrial fibrillation.
Outpatient cardiology providers will be randomly allocated into one of three groups.
The first group will receive the BPA for hypertension alone.
The second group will receive the BPA for atrial fibrillation alone.
The final group will receive both BPAs.
The rate of blood pressure control for all patients and anticoagulation in patients with atrial fibrillation in each group will be evaluated prior to and after the implementation of the BPAs to determine the effect of the BPA.
Study Type
Interventional
Enrollment (Anticipated)
7000
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 99 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- all patients seen routinely by cardiologists at Duke
Exclusion Criteria:
- none
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Atrial Fibrillation BPA
The alert will notify providers when patients with atrial fibrillation are not on anticoagulation
|
|
Other: Hypertension BPA
The alert will notify providers when patients have elevated blood pressure
|
|
Other: Atrial Fibrillation and Hypertension BPA
Providers in this arm will receive both alerts
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rates of anticoagulation among patients with atrial fibrillation
Time Frame: 1 year
|
1 year
|
Rates of hypertension control among patients seen by cardiology
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2015
Primary Completion (Actual)
August 1, 2016
Study Completion (Actual)
August 1, 2016
Study Registration Dates
First Submitted
May 4, 2015
First Submitted That Met QC Criteria
May 4, 2015
First Posted (Estimate)
May 6, 2015
Study Record Updates
Last Update Posted (Estimate)
November 30, 2016
Last Update Submitted That Met QC Criteria
November 29, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00045379
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BayerCompletedPrimary HypertensionChina
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
Clinical Trials on Best Practice Alert based in the Electronic Medical Record
-
Stanford UniversityCompleted
-
Yale UniversityAstraZenecaCompletedHeart FailureUnited States
-
McMaster UniversityCompleted
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell NeoplasmUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnHematopoietic and Lymphoid Cell Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
Geisinger ClinicRecruitingAspirin | Preeclampsia | Clinical Decision Support Systems | Economics, BehavioralUnited States
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)CompletedInfluenzaUnited States
-
Brigham and Women's HospitalBayerRecruitingChronic Kidney Diseases | Type2DiabetesUnited States
-
Yale UniversityAstraZenecaCompletedHeart Failure With Reduced Ejection FractionUnited States
-
Inova Health Care ServicesRecruitingPRagmatic Trial Of Messaging to Providers About Treatment of Heart Failure at Inova (PROMPTHF-Inova)Heart FailureUnited States